Chronic hepatitis B

17 trials 4 recruiting MedDRA PT
17 Registered trials
4 Recruiting
13 Unique sponsors
15 Unique IMPs
12 Commercial trials
Drug classes (ATC)
— ATC code not specified 12
J Anti-infectives (ATC J) 5
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 10 substances
Antiviral 3 substances
siRNA 1 substance
Interferon 1 substance
Phase III: 3 Phase II: 6 Phase I/II: 2 Phase I: 5 Phase I (First in Human): 2

Filter these 17 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 17 trials

Phase III

3 trials
  • Gilead Sciences Inc. Commercial
    TENOFOVIR DISOPROXIL
    2024-517526-26-00 1 country 2012 n=23
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    BEPIROVIRSEN
    2023-504238-23-00 9 countries 2023 n=235
    Ended
  • Gilead Sciences Inc. Academic
    TENOFOVIR DISOPROXIL
    2024-517526-26-00 1 country 2012 n=23
    Ended

Phase II

6 trials
  • Aligos Therapeutics Inc. Commercial
    ALG-000184; TENOFOVIR DISOPROXIL
    2025-521178-33-00 5 countries 2025 n=50
    Recruiting
  • Glaxosmithkline Research & Development Limited Commercial
    BEPIROVIRSEN
    2023-506867-33-01 9 countries 2022 n=108
    Ended
  • Suzhou Ribo Life Science Co. Ltd. Commercial
    RBD1016
    2023-503880-40-00 1 country 2023 n=24
    Ended
  • Vir Biotechnology Inc. Commercial
    ELEBSIRAN; PEGINTERFERON ALFA-2A; TENOFOVIR DISOPROXIL; TOBEVIBART
    2024-513176-17-00 2 countries 2023 n=13
    Ended
  • Vir Biotechnology Inc. Commercial
    ELEBSIRAN; PEGINTERFERON ALFA-2A; TOBEVIBART
    2024-513177-48-00 2 countries 2022 n=24
    Ended
  • Antwerp University Hospital Academic
    ENTECAVIR; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL
    2024-511016-25-00 1 country 2025 n=140
    Ended

Phase I/II

2 trials
  • Bluejay Therapeutics Inc. Commercial
    BJT-778
    2022-502724-46-00 3 countries n=16
    Expired
  • Klinikum der Universitaet Muenchen AöR Academic
    HEPATITIS B SURFACE ANTIGEN (RDNA); MOSAIC HBCOREAG; MVA-HBVAC
    2023-507623-36-00 1 country 2025 n=59
    Recruiting

Phase I

5 trials
  • Arbutus Biopharma Inc. Commercial
    IMP not specified
    2023-508312-39-00 3 countries 2024 n=27
    Ended
  • AstriVax Commercial
    IMP not specified
    2025-521169-28-00 1 country 2025 n=16
    Ended
  • Region Midtjylland Academic
    IMP not specified
    2023-508444-22-00 2 countries n=30
    Not authorised
  • Region Midtjylland Academic
    IMP not specified
    2023-508444-22-01 2 countries 2024 n=48
    Recruiting
  • University Medical Center Hamburg-Eppendorf Academic
    IMP not specified
    2024-514231-26-00 1 country 2025 n=30
    Ended

Phase I (First in Human)

2 trials
  • Glaxosmithkline Research & Development Limited Commercial
    BEPIROVIRSEN; GSK3965193B
    2023-509684-24-00 2 countries 2024 n=24
    Ended
  • Nchroma Bio Inc. Commercial
    MRNA3771, GRNA1599
    2025-523619-12-00 1 country 2026 n=10
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Glaxosmithkline Research & Development Limited Commercial 3 Phase II, Phase III, Phase I (First in Human) 0
Vir Biotechnology Inc. Commercial 2 Phase II 0
Gilead Sciences Inc. Commercial 2 Phase III 0
Region Midtjylland Academic 2 Phase I 1
Arbutus Biopharma Inc. Commercial 1 Phase I 0
AstriVax Commercial 1 Phase I 0
Aligos Therapeutics Inc. Commercial 1 Phase II 1
Suzhou Ribo Life Science Co. Ltd. Commercial 1 Phase II 0
Nchroma Bio Inc. Commercial 1 Phase I (First in Human) 1
Bluejay Therapeutics Inc. Commercial 1 Phase I/II 0
University Medical Center Hamburg-Eppendorf Academic 1 Phase I 0
Antwerp University Hospital Academic 1 Phase II 0
Klinikum der Universitaet Muenchen AöR Academic 1 Phase I/II 1
New trials by year
2022
2
2023
3
2024
3
2025
5
2026
1
← All indication landscapes